
a
IFX
ADA
IFX – ADA
pooled
Gene module
enriched in B cells (I) (LI.M47.0)
enriched in B cells (II) (LI.M47.1)
enriched in T cells (I) (LI.M7.0)
B cell surface signature (LI.S2)
plasma cells & B cells, immunoglobulins (LI.M156.0)
T cell activation (I) (LI.M7.1)
enriched in NK cells (I) (LI.M7.2)
enriched in B cells (III) (LI.M47.2)
enriched in B cells (VI) (LI.M69)
plasma cells, immunoglobulins (LI.M156.1)
T cell activation (II) (LI.M7.3)
T cell surface signature (LI.S0)
T cell differentiation (Th2) (LI.M19)
T cell activation and signaling (LI.M5.1)
myeloid, dendritic cell activation via NFkB (I) (LI.M43.0)
platelet activation & blood coagulation (LI.M199)
myeloid, dendritic cell activation via NFkB (II) (LI.M43.1)
platelet activation – actin binding (LI.M196)
cell adhesion (LI.M51)
enriched in activated dendritic cells/monocytes (LI.M64)
blood coagulation (LI.M11.1)
TBA (LI.M55)
cell cycle and transcription (LI.M4.0)
enriched in myeloid cells and monocytes (LI.M81)
enriched in monocytes (IV) (LI.M118.0)
Monocyte surface signature (LI.S4)
enriched in neutrophils (I) (LI.M37.1)
TLR and inflammatory signaling (LI.M16)
enriched in monocytes (II) (LI.M11.0)
immune activation – generic cluster (LI.M37.0)
0
10
20
30
40
–log10(FDR)
Direction of effect
Down at week 14
Not significant
Up at week 14
Effect size (AUC)
0.6
0.7
0.8
0.9


b
IFX
ADA
IFX – ADA
pooled
Gene module
enriched in B cells (II) (LI.M47.1)
MHC–TLR7–TLR8 cluster (LI.M146)
enriched in B cells (I) (LI.M47.0)
enriched in T cells (I) (LI.M7.0)
enriched in antigen presentation (I) (LI.M71)
enriched in NK cells (I) (LI.M7.2)
B cell surface signature (LI.S2)
antiviral IFN signature (LI.M75)
type I interferon response (LI.M127)
T cell activation (II) (LI.M7.3)
T cell activation (I) (LI.M7.1)
enriched in B cells (III) (LI.M47.2)
enriched in antigen presentation (II) (LI.M95.0)
regulation of antigen presentation and immune response (LI.M5.0)
viral sensing & immunity; IRF2 targets network (II) (LI.M111.1)
antigen processing and presentation (LI.M200)
T cell surface signature (LI.S0)
enriched in B cells (VI) (LI.M69)
cell cycle and transcription (LI.M4.0)
enriched in myeloid cells and monocytes (LI.M81)
extracellular matrix, complement (LI.M140)
enriched in monocytes (IV) (LI.M118.0)
TBA (LI.M105)
extracellular matrix (II) (LI.M2.1)
TBA (LI.M114.0)
Monocyte surface signature (LI.S4)
TLR and inflammatory signaling (LI.M16)
enriched in neutrophils (I) (LI.M37.1)
enriched in monocytes (II) (LI.M11.0)
immune activation – generic cluster (LI.M37.0)
0
10
20
30
–log10(FDR)
Direction of effect
Down at week 14
Not significant
Up at week 14
Effect size (AUC)
0.5
0.6
0.7
0.8
0.9